Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution and license agreement with KVK-Tech for their oral COVID-19 treatment.

Sen-Jam Pharmaceutical, a life sciences company developing a portfolio of anti-inflammatories by repurposing existing molecules for novel combination therapy, has entered a strategic partnership with KVK Tech, a specialty pharmaceutical manufacturing company that will be providing formulation and chemistry, manufacturing and controls (CMC) for their oral COVID-19 therapeutic. They will work in parallel with Sen-Jam teams while they complete their phase II clinical trials to have a finished product in 9-12 months. This clinical trial is another partnership between Sen-Jam and Duke-NUS Medical School.

“This is a fantastic fit for our organization,” said Kiran Vepuri, vice president of business development and brand marketing for KVK Tech. “We pride ourselves on our commitment to deliver safe, effective and affordable FDA-approved pharmaceuticals to meet our customers’ needs and ensure that patients have access to high-quality medicines when they need it. Sen-Jam and their talented team of innovators, scientists and entrepreneurs represent a perfect fit for our culture of bringing life-saving medications to the public at an affordable cost.”

The partnership was based on the values of transparency, high-quality and a commitment to cost-effectiveness. “KVK-Tech’s strong reputation and capacity to manufacture billions of tablets and capsules annually make them a great partner for our oral COVID-19 therapeutic,” said Jim Iversen, CEO, Sen-Jam.

KVK is making a strategic investment in Sen-Jam to complete all of the development work required to deliver the CMC package to the FDA for the New Drug Application (NDA) submission. In addition, KVK will have exclusive manufacturing and distribution rights for the U.S. KVK has established relationships with all of the large distributors in the US.

Sen-Jam Pharmaceutical will use the completed formulation and CMC work to establish licensing agreements with contract manufacturing companies (CMOs) around the world. The pharma company is currently in early-stage discussions with several international CMOs.